Evidence map›Paper›PMID 37993940›Full record

SynthesisBMC medicine2023

Body mass index and cancer risk among adults with and without cardiometabolic diseases: evidence from the EPIC and UK Biobank prospective cohort studies.

Emma Fontvieille, Vivian Viallon, Martina Recalde, Reynalda Cordova, Anna Jansana, Laia Peruchet-Noray, Hannah Lennon, Alicia K Heath, Dagfinn Aune, Sofia Christakoudi and 23 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 8 countries.

Emma FontvieilleNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France.
Vivian ViallonNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France.
Martina RecaldeNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France.
Reynalda CordovaNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France.
Anna JansanaNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France.
Laia Peruchet-NorayNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France.
Hannah LennonNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France.
Alicia K HeathDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Dagfinn AuneDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Sofia ChristakoudiDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Verena KatzkeDepartment of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Rudolf KaaksDepartment of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Elif Inan-ErogluDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Lene MellemkjærDanish Cancer Society Research Center, Copenhagen, Denmark.
Anne TjønnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
Kim OvervadDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Marta FarràsUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia, Bellvitge Biomedical Research Institute (IDIBELL), 08908, L'Hospitalet de Llobregat, Spain.
Dafina PetrovaEscuela Andaluza de Salud Pública (EASP), 18011, Granada, Spain.
Pilar AmianoMinistry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, 2013, San Sebastian, Spain.
María-Dolores ChirlaqueCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain.
Conchi Moreno-IribasCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain.
Sandar Tin TinCancer Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, UK.
Giovanna MasalaInstitute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Sabina SieriEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy.
Fulvio RicceriDepartment of Clinical and Biological Sciences, Centre for Biostatistics, Epidemiology, and Public Health, University of Turin, Turin, Italy.
Salvatore PanicoDepartment of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
Anne M MayJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Evelyn M MonninkhofJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Elisabete WeiderpassNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France.
Marc J GunterNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France.
Pietro FerrariNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France.
Heinz FreislingNutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, CEDEX 07, France. freislingh@iarc.who.int.ORCID 0000-0001-8648-4998
Centre international de recherche sur le cancer · FRGerman Cancer Research Center · DEUtrecht University · NLAarhus University · DKBasque Government · ESDanish Cancer Society · DKFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Institute of Human Nutrition · DEImperial College London · GBInstitut d'Investigació Biomédica de Bellvitge · ESInstituto de Investigación Biosanitaria de Granada · ESInstituto de Salud Pública de Navarra · ESInstituto Murciano de Investigación Biosanitaria · ESKing's College London · GBOsloMet – Oslo Metropolitan University · NOUniversity of Copenhagen · DKUniversity of Oxford · GBUniversity of Potsdam · DEUniversity of Turin · IT

Funding

Cancer Research UK 14136World Health Organization 001
6 · The paper itself

Abstract

backgroundWhether cancer risk associated with a higher body mass index (BMI), a surrogate measure of adiposity, differs among adults with and without cardiovascular diseases (CVD) and/or type 2 diabetes (T2D) is unclear. The primary aim of this study was to evaluate separate and joint associations of BMI and CVD/T2D with the risk of cancer.

methodsThis is an individual participant data meta-analysis of two prospective cohort studies, the UK Biobank (UKB) and the European Prospective Investigation into Cancer and nutrition (EPIC), with a total of 577,343 adults, free of cancer, T2D, and CVD at recruitment. We used Cox proportional hazard regressions to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between BMI and incidence of obesity-related cancer and in turn overall cancer with a multiplicative interaction between BMI and the two cardiometabolic diseases (CMD). HRs and 95% CIs for separate and joint associations for categories of overweight/obesity and CMD status were estimated, and additive interaction was quantified through relative excess risk due to interaction (RERI).

resultsIn the meta-analysis of both cohorts, BMI (per ~ 5 kg/m

conclusionsIrrespective of CMD status, higher BMI increased the risk of obesity-related cancer among European adults. The additive interaction between obesity and CVD suggests that obesity prevention would translate into a greater cancer risk reduction among population groups with CVD than among the general population.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2NeoplasmsAdultBiological Specimen BanksBody Mass IndexHumansObesityProspective StudiesRisk FactorsUnited KingdomCardiovascular diseasesComorbiditiesMultimorbidityObesityObesity-related cancersType 2 diabetes

Identifiers

PMID37993940
PMCPMC10666332
OpenAlexW4388924457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.